Published in Bioconjug Chem on July 17, 2002
Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease. Chem Rev (2010) 2.70
An assessment of the effects of shell cross-linked nanoparticle size, core composition, and surface PEGylation on in vivo biodistribution. Biomacromolecules (2005) 1.70
Copper-64 radiopharmaceuticals for PET imaging of cancer: advances in preclinical and clinical research. Cancer Biother Radiopharm (2009) 1.70
Peptides and peptide hormones for molecular imaging and disease diagnosis. Chem Rev (2010) 1.63
Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides. Adv Drug Deliv Rev (2008) 1.55
Cross-bridged macrocyclic chelators for stable complexation of copper radionuclides for PET imaging. Q J Nucl Med Mol Imaging (2007) 1.17
Agonist-antagonist dilemma in molecular imaging: evaluation of a monomolecular multimodal imaging agent for the somatostatin receptor. Bioconjug Chem (2007) 1.09
Clickable bifunctional radiometal chelates for peptide labeling. Chem Commun (Camb) (2010) 1.06
64Cu Core-labeled nanoparticles with high specific activity via metal-free click chemistry. ACS Nano (2012) 0.99
Microfluidic radiolabeling of biomolecules with PET radiometals. Nucl Med Biol (2012) 0.96
Nucleic acid aptamer-guided cancer therapeutics and diagnostics: the next generation of cancer medicine. Theranostics (2015) 0.87
Quantitative Accuracy of Low-Count SPECT Imaging in Phantom and In Vivo Mouse Studies. Int J Mol Imaging (2011) 0.84
64Cu-labeled 2-(diphenylphosphoryl)ethyldiphenylphosphonium cations as highly selective tumor imaging agents: effects of linkers and chelates on radiotracer biodistribution characteristics. Bioconjug Chem (2008) 0.83
claMP Tag: a versatile inline metal-binding platform based on the metal abstraction peptide. Bioconjug Chem (2014) 0.79
Isolation, characterization, and biological evaluation of syn and anti diastereomers of [(99m)Tc]technetium depreotide: a somatostatin receptor binding tumor imaging agent. J Med Chem (2007) 0.78
Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol (2006) 3.98
Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes. J Med Chem (2004) 3.57
Resolving neurotransmitters detected by fast-scan cyclic voltammetry. Anal Chem (2004) 3.18
89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J Nucl Med (2010) 2.82
Cerenkov luminescence imaging of medical isotopes. J Nucl Med (2010) 2.82
Standardized methods for the production of high specific-activity zirconium-89. Nucl Med Biol (2009) 2.77
Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease. Chem Rev (2010) 2.70
Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. Nat Chem Biol (2011) 2.42
A novel technology for the imaging of acidic prostate tumors by positron emission tomography. Cancer Res (2009) 2.30
In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur J Nucl Med Mol Imaging (2003) 2.25
Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report. Int J Radiat Oncol Biol Phys (2003) 2.09
Radiolabeling and in vivo behavior of copper-64-labeled cross-bridged cyclam ligands. J Med Chem (2002) 1.92
Preparation and biological evaluation of copper-64-labeled tyr3-octreotate using a cross-bridged macrocyclic chelator. Clin Cancer Res (2004) 1.89
Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen. Cancer Discov (2012) 1.87
Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using Zr-DFO-trastuzumab. PLoS One (2010) 1.86
Reduced sensitivity of influenza A (H5N1) to oseltamivir. Emerg Infect Dis (2007) 1.81
Imaging oxygenation of human tumours. Eur Radiol (2006) 1.78
PET imaging with ⁸⁹Zr: from radiochemistry to the clinic. Nucl Med Biol (2012) 1.74
Biodegradable dendritic positron-emitting nanoprobes for the noninvasive imaging of angiogenesis. Proc Natl Acad Sci U S A (2009) 1.72
Dynamic visualization of a joint-specific autoimmune response through positron emission tomography. Nat Immunol (2002) 1.68
Characterization of a protective monoclonal antibody recognizing Staphylococcus aureus MSCRAMM protein clumping factor A. Infect Immun (2003) 1.67
Anticancer activity of targeted proapoptotic peptides. J Nucl Med (2006) 1.59
1-11C-acetate as a PET radiopharmaceutical for imaging fatty acid synthase expression in prostate cancer. J Nucl Med (2008) 1.57
Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. Int J Radiat Oncol Biol Phys (2005) 1.56
A pretargeted PET imaging strategy based on bioorthogonal Diels-Alder click chemistry. J Nucl Med (2013) 1.52
Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone). J Nucl Med (2008) 1.51
Measurement of input functions in rodents: challenges and solutions. Nucl Med Biol (2005) 1.50
Molecular imaging of cancer with copper-64 radiopharmaceuticals and positron emission tomography (PET). Acc Chem Res (2009) 1.49
Imaging of melanoma using 64Cu- and 86Y-DOTA-ReCCMSH(Arg11), a cyclized peptide analogue of alpha-MSH. J Med Chem (2005) 1.49
A tat fusion protein-based tumor vaccine for breast cancer. Ann Surg Oncol (2005) 1.47
Minimally invasive method of determining blood input function from PET images in rodents. J Nucl Med (2006) 1.46
Synthesis, in vitro receptor binding, and in vivo evaluation of fluorescein and carbocyanine peptide-based optical contrast agents. J Med Chem (2002) 1.45
Modular strategy for the construction of radiometalated antibodies for positron emission tomography based on inverse electron demand Diels-Alder click chemistry. Bioconjug Chem (2011) 1.45
Cu-ATSM: a radiopharmaceutical for the PET imaging of hypoxia. Dalton Trans (2007) 1.42
Radiolabeling of TETA- and CB-TE2A-conjugated peptides with copper-64. Nat Protoc (2006) 1.42
Novel approach in radionuclide tumor therapy: dose enhancement by high Z-element contrast agents. Cancer Biother Radiopharm (2006) 1.42
Synthesis and biologic evaluation of 64Cu-labeled rhenium-cyclized alpha-MSH peptide analog using a cross-bridged cyclam chelator. J Nucl Med (2007) 1.42
Intraoperative imaging of positron emission tomographic radiotracers using Cerenkov luminescence emissions. Mol Imaging (2011) 1.37
Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing Neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study. Dis Colon Rectum (2008) 1.35
Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities. Eur J Nucl Med Mol Imaging (2003) 1.34
Synthesis and characterization of a macrocyclic near-infrared optical scaffold. J Am Chem Soc (2003) 1.33
Copper bis(thiosemicarbazone) complexes as hypoxia imaging agents: structure-activity relationships. J Biol Inorg Chem (2001) 1.32
Receptor-binding, biodistribution, and metabolism studies of 64Cu-DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors. Cancer Biother Radiopharm (2008) 1.30
Synthesis, characterization and in vivo studies of Cu(II)-64-labeled cross-bridged tetraazamacrocycle-amide complexes as models of peptide conjugate imaging agents. J Med Chem (2007) 1.30
A practical guide to the construction of radiometallated bioconjugates for positron emission tomography. Dalton Trans (2011) 1.28
18F-fluoroacetate: a potential acetate analog for prostate tumor imaging--in vivo evaluation of 18F-fluoroacetate versus 11C-acetate. J Nucl Med (2007) 1.25
MicroPET imaging of a gastrin-releasing peptide receptor-positive tumor in a mouse model of human prostate cancer using a 64Cu-labeled bombesin analogue. Bioconjug Chem (2003) 1.23
Unconventional nuclides for radiopharmaceuticals. Mol Imaging (2010) 1.23
Efficient (18)F-labeling of large 37-amino-acid pHLIP peptide analogues and their biological evaluation. Bioconjug Chem (2012) 1.23
In vivo evaluation of pretargeted 64Cu for tumor imaging and therapy. J Nucl Med (2003) 1.22
The growing impact of bioorthogonal click chemistry on the development of radiopharmaceuticals. J Nucl Med (2013) 1.22
Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer. Sci Signal (2014) 1.20
(64)Cu-labeled CB-TE2A and diamsar-conjugated RGD peptide analogs for targeting angiogenesis: comparison of their biological activity. Nucl Med Biol (2009) 1.14
89Zr-labeled dextran nanoparticles allow in vivo macrophage imaging. Bioconjug Chem (2011) 1.14
Optimization of labeling and metabolite analysis of copper-64-labeled azamacrocyclic chelators by radio-LC-MS. Nucl Med Biol (2005) 1.14
Alternative chelator for ⁸⁹Zr radiopharmaceuticals: radiolabeling and evaluation of 3,4,3-(LI-1,2-HOPO). J Med Chem (2014) 1.13
[Tc(CO)(3)](+) chemistry: a promising new concept for SPECT? Against. Eur J Nucl Med Mol Imaging (2003) 1.13
Evaluation of multivalent, functional polymeric nanoparticles for imaging applications. ACS Nano (2011) 1.13
18FDG-PET predicts pharmacodynamic response to OSI-906, a dual IGF-1R/IR inhibitor, in preclinical mouse models of lung cancer. Clin Cancer Res (2011) 1.13
Imaging and treating tumor vasculature with targeted radiolabeled carbon nanotubes. Int J Nanomedicine (2010) 1.12
Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET. J Nucl Med (2013) 1.12
S-nitrosothiol depletion in amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A (2006) 1.11
Assessment of myocardial blood flow using 15O-water and 1-11C-acetate in rats with small-animal PET. J Nucl Med (2006) 1.11
In-vivo electrochemistry: what can we learn about living systems? Chem Rev (2008) 1.11
Autoradiographic and small-animal PET comparisons between (18)F-FMISO, (18)F-FDG, (18)F-FLT and the hypoxic selective (64)Cu-ATSM in a rodent model of cancer. Nucl Med Biol (2008) 1.11
⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer. Eur J Nucl Med Mol Imaging (2014) 1.10
Enhancing targeted radiotherapy by copper(II)diacetyl- bis(N4-methylthiosemicarbazone) using 2-deoxy-D-glucose. Cancer Res (2003) 1.10
Preparation of high specific activity (86)Y using a small biomedical cyclotron. Nucl Med Biol (2005) 1.10
Noninvasive imaging of osteoclasts in parathyroid hormone-induced osteolysis using a 64Cu-labeled RGD peptide. J Nucl Med (2007) 1.10
Synthesis, Cu(II) complexation, 64Cu-labeling and biological evaluation of cross-bridged cyclam chelators with phosphonate pendant arms. Dalton Trans (2011) 1.10
Dysregulation of intracellular dopamine stores revealed in the R6/2 mouse striatum. J Neurochem (2009) 1.10
Preparation and biological evaluation of 64Cu-CB-TE2A-sst2-ANT, a somatostatin antagonist for PET imaging of somatostatin receptor-positive tumors. J Nucl Med (2008) 1.10
Agonist-antagonist dilemma in molecular imaging: evaluation of a monomolecular multimodal imaging agent for the somatostatin receptor. Bioconjug Chem (2007) 1.09
In vivo imaging in a murine model of glioblastoma. Neurosurgery (2007) 1.09
Validation of a novel CHX-A'' derivative suitable for peptide conjugation: small animal PET/CT imaging using yttrium-86-CHX-A''-octreotide. J Med Chem (2006) 1.07
Correlating EGFR expression with receptor-binding properties and internalization of 64Cu-DOTA-cetuximab in 5 cervical cancer cell lines. J Nucl Med (2008) 1.07
Targeting the internal epitope of prostate-specific membrane antigen with 89Zr-7E11 immuno-PET. J Nucl Med (2011) 1.07
Positron-emitting isotopes produced on biomedical cyclotrons. Curr Med Chem (2005) 1.06
Clickable bifunctional radiometal chelates for peptide labeling. Chem Commun (Camb) (2010) 1.06
The next generation of positron emission tomography radiopharmaceuticals in oncology. Semin Nucl Med (2011) 1.06
Annotating MYC status with 89Zr-transferrin imaging. Nat Med (2012) 1.06
(18)F-labeled-bioorthogonal liposomes for in vivo targeting. Bioconjug Chem (2013) 1.05
Applying PET to broaden the diagnostic utility of the clinically validated CA19.9 serum biomarker for oncology. J Nucl Med (2013) 1.05
Dosimetry of 60/61/62/64Cu-ATSM: a hypoxia imaging agent for PET. Eur J Nucl Med Mol Imaging (2005) 1.05
Identification of a novel prostate tumor target, mindin/RG-1, for antibody-based radiotherapy of prostate cancer. Cancer Res (2005) 1.04
Preparation and biological evaluation of (64)Cu labeled Tyr(3)-octreotate using a phosphonic acid-based cross-bridged macrocyclic chelator. Bioconjug Chem (2012) 1.03
A new phosphonate pendant-armed cross-bridged tetraamine chelator accelerates copper(ii) binding for radiopharmaceutical applications. Dalton Trans (2009) 1.03
Monitoring of therapy in androgen-dependent prostate tumor model by measuring tumor proliferation. J Nucl Med (2004) 1.03
Assessment of myocardial metabolism in diabetic rats using small-animal PET: a feasibility study. J Nucl Med (2006) 1.03
Preparation of 66Ga- and 68Ga-labeled Ga(III)-deferoxamine-folate as potential folate-receptor-targeted PET radiopharmaceuticals. Nucl Med Biol (2003) 1.03
In vivo biodistribution, PET imaging, and tumor accumulation of 86Y- and 111In-antimindin/RG-1, engineered antibody fragments in LNCaP tumor-bearing nude mice. J Nucl Med (2009) 1.02
Subcellular localization of radiolabeled somatostatin analogues: implications for targeted radiotherapy of cancer. Cancer Res (2003) 1.01